Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma

Kim A. Margolin, Frederick R. Aronson, Mario Sznol, Michael B. Atkins, Nicolae Ciobanu, Richard I. Fisher, Geoffrey R. Weiss, James H. Doroshow, Michael H. Bar, Michael J. Hawkins, James W. Mier, Elisabeth M. Paietta, Ellen P. Gaynor, David H. Boldt

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin’s disease and non- Hodgkin’s lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin’s disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin’s lymphoma responded (p=NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin’s disease or non-Hodgkin’s lymphomas.

Original languageEnglish (US)
Pages (from-to)214-220
Number of pages7
JournalJournal of Immunotherapy
Volume10
Issue number3
StatePublished - 1991

Fingerprint

Lymphokine-Activated Killer Cells
Hodgkin Disease
Non-Hodgkin's Lymphoma
Interleukin-2
Lymphokines
Kidney Neoplasms
Cell- and Tissue-Based Therapy
Exanthema
Antineoplastic Agents
Melanoma
Fever
Hemodynamics
Kidney
Liver
Therapeutics
Neoplasms

Keywords

  • Hodgkin’s disease
  • Interleukin-2
  • Lymphokine-activated killer cells
  • Non-Hodgkin’s lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Margolin, K. A., Aronson, F. R., Sznol, M., Atkins, M. B., Ciobanu, N., Fisher, R. I., ... Boldt, D. H. (1991). Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma. Journal of Immunotherapy, 10(3), 214-220.

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma. / Margolin, Kim A.; Aronson, Frederick R.; Sznol, Mario; Atkins, Michael B.; Ciobanu, Nicolae; Fisher, Richard I.; Weiss, Geoffrey R.; Doroshow, James H.; Bar, Michael H.; Hawkins, Michael J.; Mier, James W.; Paietta, Elisabeth M.; Gaynor, Ellen P.; Boldt, David H.

In: Journal of Immunotherapy, Vol. 10, No. 3, 1991, p. 214-220.

Research output: Contribution to journalArticle

Margolin, KA, Aronson, FR, Sznol, M, Atkins, MB, Ciobanu, N, Fisher, RI, Weiss, GR, Doroshow, JH, Bar, MH, Hawkins, MJ, Mier, JW, Paietta, EM, Gaynor, EP & Boldt, DH 1991, 'Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma', Journal of Immunotherapy, vol. 10, no. 3, pp. 214-220.
Margolin, Kim A. ; Aronson, Frederick R. ; Sznol, Mario ; Atkins, Michael B. ; Ciobanu, Nicolae ; Fisher, Richard I. ; Weiss, Geoffrey R. ; Doroshow, James H. ; Bar, Michael H. ; Hawkins, Michael J. ; Mier, James W. ; Paietta, Elisabeth M. ; Gaynor, Ellen P. ; Boldt, David H. / Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma. In: Journal of Immunotherapy. 1991 ; Vol. 10, No. 3. pp. 214-220.
@article{564330e9dc5c4815a5c666c48edfc3e0,
title = "Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma",
abstract = "Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin’s disease and non- Hodgkin’s lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin’s disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin’s lymphoma responded (p=NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin’s disease or non-Hodgkin’s lymphomas.",
keywords = "Hodgkin’s disease, Interleukin-2, Lymphokine-activated killer cells, Non-Hodgkin’s lymphoma",
author = "Margolin, {Kim A.} and Aronson, {Frederick R.} and Mario Sznol and Atkins, {Michael B.} and Nicolae Ciobanu and Fisher, {Richard I.} and Weiss, {Geoffrey R.} and Doroshow, {James H.} and Bar, {Michael H.} and Hawkins, {Michael J.} and Mier, {James W.} and Paietta, {Elisabeth M.} and Gaynor, {Ellen P.} and Boldt, {David H.}",
year = "1991",
language = "English (US)",
volume = "10",
pages = "214--220",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in hodgkin’s disease and non-hodgkin’s lymphoma

AU - Margolin, Kim A.

AU - Aronson, Frederick R.

AU - Sznol, Mario

AU - Atkins, Michael B.

AU - Ciobanu, Nicolae

AU - Fisher, Richard I.

AU - Weiss, Geoffrey R.

AU - Doroshow, James H.

AU - Bar, Michael H.

AU - Hawkins, Michael J.

AU - Mier, James W.

AU - Paietta, Elisabeth M.

AU - Gaynor, Ellen P.

AU - Boldt, David H.

PY - 1991

Y1 - 1991

N2 - Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin’s disease and non- Hodgkin’s lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin’s disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin’s lymphoma responded (p=NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin’s disease or non-Hodgkin’s lymphomas.

AB - Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin’s disease and non- Hodgkin’s lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin’s disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin’s lymphoma responded (p=NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin’s disease or non-Hodgkin’s lymphomas.

KW - Hodgkin’s disease

KW - Interleukin-2

KW - Lymphokine-activated killer cells

KW - Non-Hodgkin’s lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0025729794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025729794&partnerID=8YFLogxK

M3 - Article

C2 - 1868045

AN - SCOPUS:0025729794

VL - 10

SP - 214

EP - 220

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 3

ER -